6-K ·Filed Aug 5, 2026

KMDA

KAMADA LTD
NEUTRAL
Impact 2/10
Horizondays Processed1mo ago SEC0001213900-26-085387
Notable filing: 6-K
Actionable Insight • Neutral

No trading signal from this filing — it is purely a schedule announcement. The Q2 2026 earnings release on August 12 will be the next catalyst; monitor for revenue and adjusted EBITDA performance relative to the company's 2026 guidance ($200-205M revenue, $50-53M adjusted EBITDA per the 20-F).

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d ⚠ clustered
KMDA ▲ +16.99% at T+20d
NEUTRAL call ✓ call won +16.99% · α vs SPY +17.59% · entry $7.18 → $8.40
Next anchor: T+60d in 26d
Latest observation: T+39 +35.94% FF3 residual α
Entry anchored
Aug 5, 04:00 AM ET
via 1-min bar
T+1d
-0.56%
call -0.56% · α -0.40%
$7.14
settled 8w ago
T+5d
-4.18%
call -4.18% · α -4.53%
$6.88
settled 7w ago
T+20d
+16.99%
call +16.99% · α +17.59%
$8.40
settled 4w ago
T+60d
—
call — · α —
—
in 26d

Price Chart

Loading chart...

Executive Summary

Kamada filed a Form 6-K solely to announce the date of its Q2 and first-half 2026 financial results release (August 12, 2026) and provide conference call details. No financial results, guidance updates, or material business developments were included in this filing.

Key Facts

  • Kamada will release Q2 and first-half 2026 financial results on August 12, 2026, before U.S. market open.
  • Company will host a conference call at 8:30am ET on August 12 (dial-in and webcast provided).
  • No interim financial figures or guidance revisions were disclosed in this filing.

Financial Impact

None — this filing contains no financial results or forward-looking updates.

Risk Factors

  • Earnings release date announcement implies no material news or pre-announcement, but results could still surprise.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-085387
Document: ea030058401ex99-1.htm0001213900-26-085387
Document: 0001213900-26-085387-index-headers.html0001213900-26-085387
Document: 0001213900-26-085387-index.html0001213900-26-085387
Document: 0001213900-26-085387.txt0001213900-26-085387
18 reports for KMDA
Performance horizon
100% Hit rate 8 of 8 directional calls best @ T+20▲ +16.13%Aug 12, 2026
Filters
Rows
Reports for KMDA — sortable, filterable
TypeNow
Sep 16, 2026
16d ago
EFFECT
NEUTRAL ★ 3/10
$8.19 $8.77▲ +7.08%▲ +4.52%$8.20 (+0.12%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$7.99 $8.67▲ +8.51%▲ +9.01%$8.20 (+2.63%)
Sep 3, 2026
29d ago
Press Release
NEUTRAL ★ 2/10
$8.54 $8.31▼ −2.69%▼ −1.48%$8.20 (−3.98%)
Sep 3, 2026
29d ago
6-K
NEUTRAL ★ 2/10
$8.54 $8.31▼ −2.69%▼ −1.48%$8.20 (−3.98%)
Aug 17, 2026
6w ago
6-K / PRESS-RELEASE
BULLISH ★ 6/10
$7.76 $8.43▲ +8.63%▲ +9.82%$8.20 (+5.67%)
Aug 12, 2026
7w ago
6-K
BULLISH ★ 6/10
$6.88 $7.89▲ +14.68%▲ +15.12%$8.20 (+19.19%)
Aug 5, 2026
8w ago
6-K
NEUTRAL ★ 2/10
$7.14 $7.26▲ +1.68%▲ +0.47%$8.20 (+14.85%)
Aug 5, 2026
8w ago
6-K
NEUTRAL ★ 2/10
$7.18 $6.88▼ −4.18%▼ −4.53%$8.20 (+14.21%)
Jul 20, 2026
10w ago
6-K
BULLISH ★ 6/10
$7.09 $7.06▼ −0.42%▲ +0.00%$8.20 (+15.66%)
Jul 13, 2026
11w ago
6-K
NEUTRAL ★ 3/10
$7.17 $7.05▼ −1.67%▼ −0.89%$8.20 (+14.37%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (36h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access